MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13019-015-0379-6

Медицинская библиотека · Journal of cardiothoracic surgery · 2015

St. Jude Medical Trifecta aortic valve: results from a prospective regional multicentre registry.

Mariscalco Giovanni, Mariani Silvia, Bichi Samuele, Biondi Andrea, Blasio Andrea, Borsani Paolo, Corti Fabrizio, De Chiara Benedetta, Gherli Riccardo, Leva Cristian, Russo Claudio Francesco, Tasca Giordano, Vanelli Paolo, Alfieri Ottavio, Antona Carlo, Di Credico Germano, Esposito Giampiero, Gamba Amando, Martinelli Luigi, Menicanti Lorenzo, Paolini Giovanni, Beghi Cesare

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

The Trifecta aortic bioprosthesis (St. Jude Medical, Inc., St. Paul, MN, USA) is a stented pericardial heart valve with excellent preliminary results. Aim of the study was to evaluate its early clinical and hemodynamic performances in a multicenter regional registry.

METHODS

Between January 2011 and June 2012, 178 consecutive patients undergoing aortic valve replacement with the Trifecta bioprosthesis were prospectively enrolled at 9 Italian centers. Clinical and echocardiographic data were collectedat discharge, 6-months and at 1-year postoperatively.

RESULTS

The average age was 75.4 ± 7.7 years,and 95 (53 %) were men. Indication for valve replacement included stenosis in 123 patients (69 %), mixed lesions in 25 (14 %), and regurgitation in 30 (17 %). Ninety-three (52 %) patients were in NYHA functional class III/ IV. Hospital mortality accounted for 5 (2.8 %) patients. No valve-related perioperative complications were encountered. Median follow-up was 20.5 months (range: 1-34). Early (≤6 months) complications included one thromboembolic event, one major bleeding, and 3 endocarditis (2 explants). Two late (>6 months) thromboembolic events and two endocarditis (1 explant) were registered. No valve thrombosis or structural deterioration were observed after discharge. At 30-months, freedom from all-cause mortality was 87 %, freedom from valve-related mortality 99.4 %, freedom from endocarditis 97.5 %, and freedom from valve explants 98 %. At 1-year, mean gradients ranged from 8 to 16 mmHg, and effective orifice area indexes from 1.0 to 1.2 cm(2)/m(2) for valve sizes from 19 to 27 mm, respectively. No patients had severe prosthesis-patient mismatch.

CONCLUSIONS

Trifecta bioprosthesis provided favourable clinical and hemodynamic results over time.

Для цитирования: Mariscalco Giovanni, Mariani Silvia, Bichi Samuele, Biondi Andrea, Blasio Andrea, Borsani Paolo, Corti Fabrizio, De Chiara Benedetta, Gherli Riccardo, Leva Cristian, Russo Claudio Francesco, Tasca Giordano, Vanelli Paolo, Alfieri Ottavio, Antona Carlo, Di Credico Germano, Esposito Giampiero, Gamba Amando, Martinelli Luigi, Menicanti Lorenzo, Paolini Giovanni, Beghi Cesare. St. Jude Medical Trifecta aortic valve: results from a prospective regional multicentre registry.. Journal of cardiothoracic surgery. 2015. DOI: 10.1186/s13019-015-0379-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.